Humana (HUM) Looking Healthier

“More importantly, guidance for the full year is better than the prior guidance. That’s the important thing for them. Humana is up 8%. Very good news from them. Overall, lower prescription drug claims and medicare premiums were up. That’s good news for them. That stock is opening to the upside.” CNBC’s Squawk on the Street 4/27/2009.

Humana (HUM) reported quarterly earnings on Monday morning that got a nice gain from their government sponsored plans. There has been so much attention paid to health today with everyone worried about the swine flu that it only seemed fitting to concentrate on the healthcare sector. Humana reported earnings of $1.22 per share beating estimates by a nickel, and previous quarterly profit was more than double the company’s profit from a year ago. Sales were also better than expected, as gains from government sponsored Medicare Advantage plans more than made up for the drop off in commercial enrollment of nearly 150,000.

HumanaWhile the last quarter was pretty good, perhaps most impressively Humana raised guidance for the second quarter and the full year. Shares are rose in morning trading more than 7%. We at Ockham have viewed Humana as Undervalued for some time now, as the fundamentals seem to easily support the now much lower price levels. The current price-to-sales and price-to-cash flow metrics for Humana are well below the historically normal range. In addition to this, healthcare stocks after taking quite a hit recently are ranked as the most attractive sector for valuations.

However, our optimism is tempered a bit by the fact that Humana has become so dependent on the Medicare programs, funding to which many expect to fall off in the next year. Even though this was a strength in the last quarter, it could very easily hurt the bottom line going forward.

Humana Looking Healthier

About Ockham Research 645 Articles

Ockham Research is an independent equity research provider based in Atlanta, Georgia. Security analysis at Ockham Research is based upon the principle known as Ockham's Razor, named for the 14th- century Franciscan friar, William of Ockham. The principle states that a useful theory should utilize as few elements as possible, because efficiency is valuable. In this spirit, our goal is to make the investing environment as simple and understandable as possible, yet no simpler than is necessary.

We utilize this straightforward approach to value over 5500 securities, with key emphasis given to the study of individual securities' price-to-sales, price-to-cash earnings and other historical valuation ranges. Our long term value investing methodology is powered by the teachings of Ben Graham and it has proven to be very adept at identifying stock prices that are out of line with fundamental factors.

Ockham Research provides its research in a variety of forms and products including our company specific reports, portfolio analytics tools, newsletters, and blog posts. We also offer a white labeling research solution that can give any financial services firm their own research presence without the time and cost associated with building such a robust coverage universe of their own.

Be the first to comment

Leave a Reply

Your email address will not be published.